Trial
NCT01116661
Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of California, San Francisco
Collaborators
—
Condition
Glioma
Intervention
5-Aminolevuline Acid (ALA)
Why stopped
The primary objective for high grade gliomas has been met and the FDA has now approved the drug (Gleolan) for use in the United States.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-29